K-numberK253631
Device nameMobility Scooter (CL-Q3, CL-Q4)
ApplicantZhejiang Wei Ling New Energy Technology Co., Ltd.
Product codeINI
Device classClass II
Decision dateFeb 23, 2026
DecisionSubstantially Equivalent
Regulation890.3800
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Mobility Scooter (CL-Q3, CL-Q4) is a motor-driven indoor and outdoor transportation vehicle designed to provide mobility to disabled or elderly persons limited to a seated position. It features two front wheels, two rear wheels, two support wheels, a seat, tiller console, electric motor, electromagnetic brake, rechargeable battery with off-board charger, and key switch, with movement controlled by throttle lever and speed dial.

Technological characteristics

The subject device differs from the predicate in several specifications: battery type (Sealed Lead Acid 12V/20Ah×3 or Li-ion 36V/15Ah versus Lithium 25.6Vdc 15Ah), ground clearance (65mm or 60mm versus 20mm), max speed (6 km/h versus 7.92 km/h), max slope (10° or 6° versus 6°), and charger output (DC44.25V/3.0A or DC42V/3.0A versus 29.4V/2A). The submitter asserts these differences do not impact safety or effectiveness when evaluated under applicable ISO 7176 standards.

Test standards cited

ISO 7176 series (Parts 1-15, 21-22, 25), ISO 16840-10 (resistance to ignition), IEC 60601-1-2 (electromagnetic compatibility), and ISO 10993 (biocompatibility). The device also received Enhanced-level software documentation in accordance with FDA's 2023 Guidance on device software functions.

Substantial equivalence argument

Both the subject and predicate devices comply with the same comprehensive ISO 7176 standards and demonstrate equivalent performance across static stability, dynamic stability, braking, distance range, dimensions, mass, seating, durability, obstacle climbing, and EMC testing. The minor parametric differences (battery chemistry, speed, slope rating) do not introduce new safety or effectiveness concerns when evaluated under the same standardized testing framework. No clinical testing was required given the demonstrated substantial equivalence in non-clinical performance data.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →